A video and a paper, descibing a UK study of Covid vaccine (AZ and Pfizer) efficiency for CLL patients, are available.
I'd be interested in both patient and professional responses to this.
I'm on Watch+Wait and it makes me guardedly optimisitic.
Here's how I got it and what mterial is where....
My Google Scholar Alert -
"cll" covid vaccine
- today yeilded an email alert -
Dr Helen Parry presents the findings of research into vaccine effectiveness - CLL Support Association
CLL Support Association
This vital research shows how effective the Covid-19 vaccine is for CLL patients. Dr Parry outlines the findings in an easy to understand way.
The video (20 minutes) is very clear and relatively jargon free-
A Google Scholar search -
helen parry cll
- with dates restricted to 2021 yielded, as first result -
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
HM Parry, G McIlroy, R Bruton, M Ali, C Stephens… - 2021 - papers.ssrn.com
Background: B cell chronic lymphocytic leukaemia (CLL) is associated with immune
suppression and patients are at increased clinical risk following SARS-CoV-2 infection.
Covid-19 vaccines offer the potential for protection against severe infection but relatively …
Cited by 1 All 2 versions
- with link to paper clearly detailing the same study -
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3845994
If you find the PDF link to the full paper paywalled then get in touch. I acquired it by using a cookie-free browser but if that doesn't work for you then I can send it along. I'm on jid@flying-boat.co.uk
Abstract -
Background
B cell chronic lymphocytic leukaemia (CLL) is associated with immune suppression
and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19
vaccines offer the potential for protection against severe infection but relatively little is
known regarding the profile of the antibody response following first or second
vaccination.
Methods
We studied spike-specific antibody responses following first and/or second Covid-19
vaccination in 299 patients with CLL compared with healthy donors. 13 patients
underwent a standard interval (3-week) vaccine regimen whilst 286 underwent
extended interval (10-12 week) vaccination. 154 patients received the BNT162b2
mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either
by venepuncture or as dried blood spots on filter paper. 267 samples were taken at 5
weeks after the first vaccine for patients on the extended interval regimen and 13 and
42 samples were taken at 2-4 weeks after the second vaccine in patients on the
standard or extended vaccine regimens respectively.
Findings
Spike-specific antibody responses were detectable in 34% of patients with CLL after
one vaccine compared to 94% in healthy donors with antibody titres 104-fold lower in
the patient group. Antibody responses increased to 75% after second vaccine,
compared to 100% in healthy donors, although titres remained lower. Multivariate
analysis showed that current treatment with BTK inhibitors or IgA deficiency were
independently associated with failure to generate an antibody response after the
second vaccine.
Interpretation
This preprint research paper has not been peer reviewed. Electronic copy available at: ssrn.com/abstract=3845994
Preprint not peer reviewed
Antibody responses after both the first and second Covid-19 vaccine are lower in
patients with CLL compared to age-matched donors. This is particularly marked in
patients who are taking BTK inhibitors or have serum IgA deficiency. Further
approaches such as repeat vaccination or administration of prophylactic antibody may
be worthy of investigation for some patients.
